Day Begin Period Cash Flow from 2010 to 2024

DAWN Stock  USD 13.72  0.38  2.85%   
Day One Begin Period Cash Flow yearly trend continues to be very stable with very little volatility. Begin Period Cash Flow is likely to grow to about 97.1 M this year. Begin Period Cash Flow is the amount of cash Day One Biopharmaceuticals has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
85.3 M
Current Value
97.1 M
Quarterly Volatility
75.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Day One financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Day One's main balance sheet or income statement drivers, such as Net Interest Income of 5.7 M, Depreciation And Amortization of 34.2 K or Interest Expense of 5.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.53. Day financial statements analysis is a perfect complement when working with Day One Valuation or Volatility modules.
  
Check out the analysis of Day One Correlation against competitors.

Latest Day One's Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of Day One Biopharmaceuticals over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Day One's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Day One's overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Slightly volatile
   Begin Period Cash Flow   
       Timeline  

Day Begin Period Cash Flow Regression Statistics

Arithmetic Mean36,479,804
Geometric Mean4,098,838
Coefficient Of Variation207.54
Mean Deviation48,603,446
Median942,000
Standard Deviation75,708,549
Sample Variance5731.8T
Range283.4M
R-Value0.60
Mean Square Error3946.7T
R-Squared0.36
Significance0.02
Slope10,166,062
Total Sum of Squares80245T

Day Begin Period Cash Flow History

202497.1 M
202385.3 M
2022284.3 M
202143.7 M
202027.3 M

About Day One Financial Statements

Day One investors utilize fundamental indicators, such as Begin Period Cash Flow, to predict how Day Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Begin Period Cash Flow85.3 M97.1 M

Pair Trading with Day One

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.

Moving against Day Stock

  0.47MTEM Molecular TemplatesPairCorr
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:
Check out the analysis of Day One Correlation against competitors.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.97)
Revenue Per Share
1.144
Return On Assets
(0.25)
Return On Equity
(0.18)
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.